EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Prognostic biomarkers for enhanced risk stratification in extraskeletal myxoid chondrosarcoma: a retrospective cohort study

Amphun Chaiboonchoe, Jantappapa Chanthercrob, Romgase Sakamula, Thanaphon Likhityungyuen, Sorranart Muangsomboon, Jomjit Chantharasamee, Francis Lee, Krittawat Suwanpukdee, Pannin Thanapipatsiri, Rapin Phimolsarnti, Apichat Asavamongkolkul, Somponnat Sampattavanich und 1 weitere

PeerJ · 13.07.2026 · 14 · e21497

DOI: 10.7717/peerj.21497 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PeerJ, online erschienen am 13.07.2026. Verfasst von Amphun Chaiboonchoe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospit…. Hauptthemen laut MEDLINE: Chondrosarcoma, Neoplasms, Connective and Soft Tissue, Biomarkers, Tumor. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University and Siriraj Foundation, Research Excellence Development (RED) Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft-tissue sarcoma driven by the EWSR1::NR4A3 fusion. Its unpredictable clinical course and lack of validated molecular prognostic tools complicate patient treatment.

Methods

We performed whole-transcriptome targeted RNA sequencing (TempO-Seq) on archival formalin-fixed paraffin-embedded (FFPE) tumor specimens from 12 molecularly confirmed EMC cases. To explore potential biological markers, the cohort was stratified into good-prognosis ( n = 6; overall survival (OS) >8 years) and poor-prognosis ( n = 6; OS < 8 years) groups. We conducted differential expression analysis, gene set enrichment analysis (GSEA), and applied least absolute shrinkage and selection operator (LASSO)–Cox regression with bootstrap validation (1,000 iterations). Candidate genes were cross-validated using 31 external EMC cases across public microarray and NGS datasets. Immune infiltration was estimated computationally and spatially validated via multiplex immunofluorescence (mIF) on two representative specimens.

Results

We identified 550 differentially expressed genes and derived a three-gene prognostic candidate ( PXN, TYMS, H1FX ) that stratified patients by overall survival in the training cohort (log-rank P = 0.0099), despite internal validation indicating model overfitting. H1FX was significantly upregulated in EMC versus other cartilaginous tumors across independent datasets ( P = 0.001). Immune profiling revealed higher B-cell infiltration in low-risk tumors ( P = 0.005). Proof-of-concept mIF in two specimens suggested a spatially localized immunosuppressive microenvironment in the high-risk tumor, with increased exhausted CD3 + CD8 + PD1 + T cells ( P = 6.4 × 10 −5 ), FOXP3 + regulatory T cells ( P = 0.006), and elevated PXN protein expression ( P = 0.008). All mIF comparisons are within-specimen region of interest (ROI) analyses and should be interpreted as hypothesis-generating.

Conclusions

This integrated transcriptomic and spatial immune characterization identifies PXN, TYMS, and H1FX as exploratory EMC biomarker candidates, with PXN showing the most consistent cross-platform support. Immune microenvironment heterogeneity in EMC warrants further investigation. Given the small cohort and model overfitting, these findings are exploratory. Prospective validation in larger, multi-center cohorts is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaNeoplasms, Connective and Soft TissueBiomarkers, TumorHumansFemaleRetrospective StudiesMalePrognosisMiddle AgedAgedAdultRisk AssessmentTranscriptomeGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Extraskeletal myxoid chondrosarcomaLASSO–CoxregressionPrognostic biomarkersTempO-SeqTumor immune microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Orthopaedics and Rehabilitation, Yale University, Connecticut, United States of America.
  • Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Förderung

  • Siriraj Research Fund
  • Faculty of Medicine Siriraj Hospital, Mahidol University and Siriraj Foundation
  • Research Excellence Development (RED) Program

Zitieren

APA

Chaiboonchoe, A., Chanthercrob, J., Sakamula, R., Likhityungyuen, T., Muangsomboon, S., Chantharasamee, J., Lee, F., Suwanpukdee, K., Thanapipatsiri, P., Phimolsarnti, R., Asavamongkolkul, A., Sampattavanich, S., & Chandhanayingyong, C. (2026). Prognostic biomarkers for enhanced risk stratification in extraskeletal myxoid chondrosarcoma: a retrospective cohort study. PeerJ, 14, e21497. https://doi.org/10.7717/peerj.21497

Vancouver

Chaiboonchoe A, Chanthercrob J, Sakamula R, Likhityungyuen T, Muangsomboon S, Chantharasamee J, et al. Prognostic biomarkers for enhanced risk stratification in extraskeletal myxoid chondrosarcoma: a retrospective cohort study. PeerJ. 2026;14:e21497. doi:10.7717/peerj.21497

BibTeX
@article{Chaiboonchoe2026,
  author = {Chaiboonchoe, Amphun and Chanthercrob, Jantappapa and Sakamula, Romgase and Likhityungyuen, Thanaphon and Muangsomboon, Sorranart and Chantharasamee, Jomjit and Lee, Francis and Suwanpukdee, Krittawat and Thanapipatsiri, Pannin and Phimolsarnti, Rapin and Asavamongkolkul, Apichat and Sampattavanich, Somponnat and Chandhanayingyong, Chandhanarat},
  title = {Prognostic biomarkers for enhanced risk stratification in extraskeletal myxoid chondrosarcoma: a retrospective cohort study},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21497},
  doi = {10.7717/peerj.21497}
}
Kostenlos starten →